Loading...
•
Dec 31, 2022
Pulse Biosciences Q4 2022 Earnings Report
Announced financial results, reporting no revenue due to discontinuation of commercial dermatology activity and reduced cash usage.
Key Takeaways
Pulse Biosciences reported no revenue for Q4 2022 due to the discontinuation of commercial dermatology activity. The company reduced its cash usage and is focusing on advancing its nsPFA technology for electrophysiology and atrial fibrillation treatment.
Advanced development of the nsPFA cardiac ablation catheter system intending to pursue a first-in-human safety feasibility study.
AF Symposium poster presentation demonstrated the ability of the Company’s nsPFA catheter system to perform cardiac ablation and mapping with a single catheter in preclinical studies.
Reduced fourth quarter 2022 cash usage to $8.0 million dollars, a reduction of $2.6 million compared to the third quarter of 2022 and in-line with prior guidance.
Cash on hand is expected to be sufficient to fund planned operations into the third quarter of 2024.
Forward Guidance
Pulse Biosciences will remain focused on advancing the development and regulatory progress for both devices in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...